Study on drug release and stability of matrix tablet contained monoammonium glycyrrhizinate

Please cite this article as: Jambaninj D et al., Study on drug release and stability of matrix tablet contained monoammonium glycyrrhizinate. American Journal of PharmTech Research 2019. Study on drug release and stability of matrix tablet contained monoammonium glycyrrhizinate Otgonsuren.D, Davaasuren.Ts,Enkhtuul.B, Davaadagva.D, Jambaninj.D 1.Department of pharaceutical technology, School of Pharmacy, Mongolian National University of Medical Sciences ABSTRACT Monoammonium glycyrrhizinate was determined it has anti-viral activity in case of hepatitis A, B, C, D. We have developed matrix tablet contained monoammonium glycyrrhizinate by previous study. The objective of the study was to evaluate drug release of matrix tablet in vivo and determinate its stability. In the present study was evaluated in vivo drug release of the matrix tablet. Stability testing was 230 determinated by long term and accelerated method by such criteria’s: appearance, weight variation, biological active compound, hardness, friability, dissolution and microbiological contamination. The Cmax (μg/ml), Tmax (h), AUC0-t (μg h/ml) of Glycyron tablet and Licozinat matrix tablet were determined in vivo. Stability of the matrix tablet was determined. Licozinat matrix tablet was released drug by prolonged time by in vitro. In vivo pharmacokinetic study in rabbits confirmed the prolonged release by showing increase in bioavailability for matrix tablet compared to Glycyron tablet. Licozinat matrix tablet was stable for 12 months. Stability testing of matrix tablet is continuing by long term method.